mir-885 microRNA precursor family
| mir-885 | |
|---|---|
| Identifiers | |
| Symbol | mir-885 |
| Rfam | RF01015 |
| miRBase family | MIPF0000532 |
| Other data | |
| RNA type | microRNA |
| Domain(s) | Eukaryota; |
| PDB structures | PDBe |
In molecular biology mir-885 microRNA is a short RNA molecule. MicroRNAs function to regulate the expression levels of other genes by several mechanisms.
miR-885-5p in neuroblastoma
The miR-885-5p form of this microRNA acts as a tumour suppressor in neuroblastoma, through interference with cell cycle progression and cell survival. It is found at 3p25.3, a chromosome region frequently deleted in primary neuroblastoma,[1] and expression results in p53 protein accumulation and pathway activation. Altered expression of multiple genes is observed with miR-885-5p, including the CDK2 and MCM5 genes encoding cyclin-dependent kinase 2 and mini-chromosome maintenance protein MCM5, and also with several p53 target genes.[1]
Biological Implication
Clinical Biomarker
Circulating miRNAs (microRNAs) are emerging as promising biomarkers for several pathological conditions. similarly, miR-885-5p found as a potential marker for liver disease condition. It is significantly elevated in the patients sera with liver pathologies, and researcher suggested that serum miRNAs could serve as novel complementary biomarkers for the detection and assessment of liver pathologies.[2] These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in colorectal cancer (CRC). The direct comparison of expression patterns of metastasis-specific microRNAs (miRNAs) in primary CRCs (pCRCs) and matched liver metastases (LMs) provides a feasibility of their clinical application as metastasis-specific biomarkers.[3] In a clinical study it has been found that miR-885-5p is increased in plasma from pre-eclampsia compared with healthy pregnant women, and it is released into circulation mainly inside exosomes.[4]
Cancer
In search of an effective therapeutic strategy for improving colon cancer treatment, a novel role of miR-885-3p has been observed in tumor angiogenesis by targeting BMPR1A, which regulates a proangiogenic factor, and provide new evidence that targeting miRNAs might be an effective therapeutic strategy.[5]
See also
References
- ^ a b Afanasyeva EA, Mestdagh P, Kumps C, Vandesompele J, Ehemann V, Theissen J, et al. (2011). "MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival". Cell Death Differ. 18 (6): 974–84. doi:10.1038/cdd.2010.164. PMC 3131937. PMID 21233845.
- ^ Gui, Junhao; Tian, Yaping; Wen, Xinyu; Zhang, Wenhui; Zhang, Pengjun; Gao, Jing; Run, Wei; Tian, Liyuan; Jia, Xingwang (2011-03-01). "Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies". Clinical Science. 120 (5): 183–193. doi:10.1042/CS20100297. ISSN 1470-8736. PMC 2990200. PMID 20815808.
- ^ Hur, Keun; Toiyama, Yuji; Schetter, Aaron J.; Okugawa, Yoshinaga; Harris, Curtis C.; Boland, C. Richard; Goel, Ajay (March 2015). "Identification of a metastasis-specific MicroRNA signature in human colorectal cancer". Journal of the National Cancer Institute. 107 (3). doi:10.1093/jnci/dju492. ISSN 1460-2105. PMC 4334826. PMID 25663689.
- ^ Sandrim, V. C.; Luizon, M. R.; Palei, A. C.; Tanus-Santos, J. E.; Cavalli, R. C. (December 2016). "Circulating microRNA expression profiles in pre-eclampsia: evidence of increased miR-885-5p levels". BJOG: An International Journal of Obstetrics and Gynaecology. 123 (13): 2120–2128. doi:10.1111/1471-0528.13903. ISSN 1471-0528. PMID 26853698.
- ^ Xiao, F.; Qiu, H.; Cui, H.; Ni, X.; Li, J.; Liao, W.; Lu, L.; Ding, K. (2015-04-09). "MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling". Oncogene. 34 (15): 1968–1978. doi:10.1038/onc.2014.134. ISSN 1476-5594. PMID 24882581.
Further reading
- Huang, Y.; Chuang, A. Y.; Ratovitski, E. (2011). "Phospho-ΔNp63α/miR-885-3p axis in tumor cell life and cell death upon cisplatin exposure". Cell Cycle. 10 (22): 3938–3947. doi:10.4161/cc.10.22.18107. PMC 3266119. PMID 22071691.
- Yan, W.; Zhang, W.; Sun, L.; Liu, Y.; You, G.; Wang, Y.; Kang, C.; You, Y.; Jiang, T. (2011). "Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme". Brain Research. 1411: 108–115. doi:10.1016/j.brainres.2011.07.002. PMID 21831363. S2CID 206327968.
- Tömböl, Z. F.; Eder, K.; Kovács, A.; Szabó, P. M.; Kulka, J.; Likó, I. N.; Zalatnai, A.; Rácz, G.; Tóth, M. S.; Patócs, A.; Falus, A. S.; Rácz, K. R.; Igaz, P. (2010). "MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas". Modern Pathology. 23 (12): 1583–1595. doi:10.1038/modpathol.2010.164. PMID 20818339.
- Gui, J.; Tian, Y.; Wen, X.; Zhang, W.; Zhang, P.; Gao, J.; Run, W.; Tian, L.; Jia, X.; Gao, Y. (2011). "Serum microRNA characterization identifiesmiR-885-5pas a potential marker for detecting liver pathologies". Clinical Science. 120 (5): 183–193. doi:10.1042/CS20100297. PMC 2990200. PMID 20815808.
- Guled, M.; Lahti, L.; Lindholm, P. M.; Salmenkivi, K.; Bagwan, I.; Nicholson, A. G.; Knuutila, S. (2009). "CDKN2A,NF2, andJUNare dysregulated among other genes by miRNAs in malignant mesothelioma-A miRNA microarray analysis". Genes, Chromosomes and Cancer. 48 (7): 615–623. doi:10.1002/gcc.20669. PMID 19396864. S2CID 22482567.
External links
 | This genetics article is a stub. You can help Wikipedia by expanding it. |